BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Upstate Awarded $207k Grant From National Cancer Institute


10/19/2005 5:11:40 PM

CHARLOTTESVILLE, Va., June 7 /PRNewswire/ -- Upstate, in collaboration with the University of Virginia Health Science Center, has been granted a Phase I STTR (Small Business Technology Transfer) award in the amount of $207,522 by The National Cancer Institute in Bethesda, MD. The grant is to fund initial experiments to develop novel small molecule inhibitors of histone acetyltransferase enzymes (HATs), important regulators of genome function.

Abberant HAT function is common in several types of cancer, and the development of inhibitors to HATs could lead to future progress in cancer therapeutics. Cancer primarily involves the dysregulation of cell proliferation and cell signaling. Cell signaling, Upstate's core business, is a common theme in cancer research and drug discovery.

About the Grant

Federal agencies with qualifying research and development budgets are required to allocate 0.3 percent to cooperative research. The STTR award mandates that work be conducted jointly with a business performing at least 40 percent of the work and a non-profit research institution performing at least 30 percent. Under the grant structure, positive peer reviewed results at the end of Phase I (next year) could lead to an additional grant approval for Phase II and a dramatic increase in funding.

"We are extremely pleased to have this opportunity to work with the University of Virginia Health Science Center on this project. This type of research can lead to the development of novel cancer treatment protocols," said James Bone, Ph.D., a Research and Development Manager for Upstate. While Upstate and UVA have long had a relationship, this is the first time the two will perform joint research.

Upstate is the leading supplier of innovative cell signaling products, technology, platforms and services. Founded in 1988, Upstate provides researchers at pharmaceutical and biotechnology companies, universities and government agencies with advanced tools to accelerate life science research and drug discovery. Upstate's global reach includes six locations in the U.S. and Europe with key technology centers in its Charlottesville, VA headquarters; Lake Placid, NY; and Dundee and Cambridge in the U.K.

CONTACT: Reese A. Nank, APR, of Reputations PR and Marketing, +1-410-218-9121, or reputationspr@cox.net, for Upstate.

Upstate

CONTACT: Reese A. Nank, APR, of Reputations PR and Marketing,+1-410-218-9121, or reputationspr@cox.net, for Upstate


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->